Skip to main content
. Author manuscript; available in PMC: 2019 Aug 12.
Published in final edited form as: Oncogene. 2018 Aug 3;37(50):6463–6476. doi: 10.1038/s41388-018-0424-8

Fig. 4.

Fig. 4

RANBP9 levels are predictive of response to platinum in NSCLC patients. a Kaplan–Meier curves representing the progression free survival (PFS) of RANBP9-low (blue line) and -high (red line) NSCLC patients treated with platinum compound as first-line. b Kaplan–Meier curves representing the overall survival (OS) of the same population as in (a)